Abstract
Ovarian cancer is the most lethal gynecological cancer due to lack of clear symptom and reliable screening biomarker in the early stage. The capability to detect the initiation of malignancy with a sensitive and effective approach is one of the most desirable goals for ovarian cancer therapy. In this study, we spearheaded noninvasive detection of ovarian cancer by salivary transcriptomic biomarkers, and evaluated the clinical utilities of discovered biomarkers using a clinical case–control study. To find salivary mRNA biomarkers, salivary transcriptomes in 11 ovarian cancer patients and 11 matched controls were profiled by Affymetrix HG-U133-Plus-2.0 array. The biomarker candidates selected from the microarray results were then subjected to clinical validation by RT-qPCR using an independent sample cohort including 21 ovarian cancer patients and 35 healthy controls. Seven downregulated mRNA biomarkers were validated. The logistic regression model revealed the combination of five validated biomarkers (AGPAT1, B2M, BASP2, IER3, and IL1B) can significantly discriminate ovarian cancer patients (n = 21) from the healthy controls (n = 35), yielding a receiver operating characteristic plot, area under the curve value of 0.909 with 85.7% sensitivity and 91.4% specificity. In summary, we have demonstrated that the RNA signatures in saliva could serve as biomarkers for detection of ovarian cancer with high sensitivity and specificity. This emerging approach with high-throughput, noninvasive, and effective advantages provides a feasible means for detection of systemic cancer, and opens a new avenue for early disease detection.
Similar content being viewed by others
References
Kandalaft LE, Motz GT, Duraiswamy J, Coukos G (2011) Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev 30:141–151
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59:225–249
Verheijen RHM, Von Mensdorff-Pouilly S, Van Kamp GJ, Kenemans P (1999) CA125: fundamental and clinical aspects. Cancer Biol 9:117–124
van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC Jr, Hacker NF (2001) OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 92:2837–2844
Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast RC Jr, Zhang Z, Nicoletto MO, Donach M, Yu Y et al (2010) Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol 31:209–215
Fleischer A (eds) (1997) Ovarian cancer. In: Fleischer AC, Javitt MC, Jeffrey RB, Jones HW Clinical Gynecologic Imaging. Lippincott Williams & Wilkins, Philadelphia, pp 107
Bast RC Jr (2004) Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Trans Am Clin Climatol Assoc 115:233–248
Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC et al (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572–577
Tchagang AB, Tewfik AH, DeRycke MS, Skubitz KM, Skubitz AP (2008) Early detection of ovarian cancer using group biomarkers. Mol Cancer Ther 7:27–37
Wei SH, Balch C, Paik HH, Kim YS, Baldwin RL, Liyanarachchi S, Li L, Wang Z, Wan JC, Davuluri RV (2006) Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 12:2788–2794
Hu S, Wang J, Meijer J, Ieong S, Xie Y, Yu T, Zhou H, Henry S, Vissink A, Pijpe J et al (2007) Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum 56:3588–3600
Li Y, St John MA, Zhou X, Kim Y, Sinha U, Jordan RC, Eisele D, Abemayor E, Elashoff D, Park NH et al (2004) Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 10:8442–8450
Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT (2009) Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 15:5473–5477
Rao PV, Reddy AP, Lu X, Dasari S, Krishnaprasad A, Biggs E, Roberts CT, Nagalla SR (2009) Proteomic identification of salivary biomarkers of type-2 diabetes. J Proteome Res 8:239–245
Zhang L, Farrell JJ, Zhou H, Elashoff D, Akin D, Park NH, Chia D, Wong DT (2010) Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology 138:949–957
Zhang L, Xiao H, Karlan S, Zhou H, Gross J, Elashoff D, Akin D, Yan X, Chia D, Karlan B et al (2010) Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One 5:e15573
Chen DX, Schwartz PE, Li FQ (1990) Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol 75:701–704
Boucaud M, Pinguet F, Poujol S, Romieu G, Cupissol D, Astre C, Culine S, Bressolle F (2001) Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer. Eur J Cancer 37:2357–2364
Ballantyne J (2007) Validity of messenger RNA expression analyses of human saliva. Clin Cancer Res 13:1350–1351
Li Y, Zhou X, St John MA, Wong DT (2004) RNA profiling of cell-free saliva using microarray technology. J Dent Res 83:199–203
Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55:611–622
Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39:561–577
Carpenter B, Hill KJ, Charalambous M, Wagner KJ, Lahiri D, James DI, Andersen JS, Schumacher V, Royer-Pokora B, Mann M et al (2004) BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1. Mol Cell Biol 24:537–549
Li Y, Elashoff D, Oh M, Sinha U, St John MA, Zhou X, Abemayor E, Wong DT (2006) Serum circulating human mRNA profiling and its utility for oral cancer detection. J Clin Oncol 24:1754–1760
Arlt A, Schäfer H (2011) Role of the immediate early response 3 (IER3) gene in cellular stress response, inflammation and tumorigenesis. Eur J Cell Biol 90:545–552
Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WH, Zhang Z, Petillo D et al (2011) Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res 71:3162–3172
Hernádi Z, Molnár V, Juhász B, Pólka R, Margitai B (1992) Predictive value of the tumor marker combination CA-125 and beta-2-microglobulin in ovarian cancer. Zentralbl Gynakol 114:6–9
Yang HS, Li Y, Deng HX, Peng F (2009) Identification of beta2-microglobulin as a potential target for ovarian cancer. Cancer Biol Ther 8:2323–2328
Bushley AW, Ferrell R, McDuffie K, Terada KY, Carney ME, Thompson PJ, Wilkens LR, Tung KH, Ness RB, Goodman MT (2004) Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol 95:672–679
Cheng L, Lu W, Kulkarni B, Pejovic T, Yan X, Chiang JH, Hood L, Odunsi K, Lin B (2010) Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologies. Gynecol Oncol 117:159–169
Landman AD, Sanford LM, Howland BE, Dawes C, Pritchard ET (1976) Testosterone in human saliva. Experientia 32:940–941
Hammond GL, Langley MS (1986) Identification and measurement of sex hormone binding globulin (SHBG) and corticosteroid binding globulin (CBG) in human saliva. Acta Endocrinol (Copenh) 112:603–608
Kubagawa H, Bertoli LF, Barton JC, Koopman WJ, Mestecky J, Cooper MD (1987) Analysis of paraprotein transport into saliva by using anti-idiotype antibodies. J Immunol 138:435–439
Gao K, Zhou H, Zhang L, Lee JW, Zhou Q, Hu S, Wolinsky LE, Farrell J, Eibl G, Wong DT (2009) Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer. PLoS One 4:e5875
Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100:1432–1438
Acknowledgments
This work was supported by National Research Foundation of Korean government (KRF-2008-314-E00121 and 2011–0010286).
Disclosure statement
David T. Wong is co-founder of RNAmeTRIX Inc., a molecular diagnostic company.
Author information
Authors and Affiliations
Corresponding author
Additional information
Yu-Hsiang Lee and Jae Hoon Kim contributed equally to this manuscript.
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOC 334 kb)
Rights and permissions
About this article
Cite this article
Lee, YH., Kim, J.H., Zhou, H. et al. Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma. J Mol Med 90, 427–434 (2012). https://doi.org/10.1007/s00109-011-0829-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-011-0829-0